Cargando…

Single-centre experience of refractory rheumatoid arthritis

OBJECTIVES: The aim was to evaluate the proportion of RA patients who are refractory to multiple targeted therapies (TTs) in a real-world cohort of patients in a tertiary rheumatology referral centre, to describe patterns of drug sequencing associated with the development of refractory RA (RefRA) an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fitton, John, Melville, Andrew, Naraghi, Kamran, Nam, Jacqueline, Dass, Shouvik, Emery, Paul, Buch, Maya H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9348550/ https://www.ncbi.nlm.nih.gov/pubmed/35937776 http://dx.doi.org/10.1093/rap/rkac057

Ejemplares similares

Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008)

Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy
por: Ouboussad, Lylia, et al.
Publicado: (2019)

Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2018)

A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA)
por: Dumitru, Raluca B., et al.
Publicado: (2016)

Tofacitinib in the treatment of active rheumatoid arthritis – single-centre experience
por: Madej, Marta, et al.
Publicado: (2019)

Muscle deterioration due to rheumatoid arthritis: assessment by quantitative MRI and strength testing
por: Farrow, Matthew, et al.
Publicado: (2020)

Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations
por: Horton, Sarah, et al.
Publicado: (2010)

'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps
por: Tan, Yvonne, et al.
Publicado: (2022)

Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
por: Md Yusof, Md Yuzaiful, et al.
Publicado: (2023)

Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial
por: Erhayiem, Bara, et al.
Publicado: (2014)

Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis
por: Ouboussad, L., et al.
Publicado: (2017)

Quality of Life and Depression in Rheumatoid Arthritis Patients Treated with Biologics – A Single Centre Experience
por: Tański, Wojciech, et al.
Publicado: (2022)

Intravenous pamidronate for refractory rheumatoid arthritis
por: Salesi, Mansour, et al.
Publicado: (2012)

Cardiovascular effects of biological versus conventional synthetic disease-modifying antirheumatic drug therapy in treatment-naïve, early rheumatoid arthritis
por: Plein, Sven, et al.
Publicado: (2020)

Rituximab in refractory sarcoidosis: a single centre experience
por: Cinetto, Francesco, et al.
Publicado: (2015)

Changes in the pharmacological management of rheumatoid arthritis over two decades
por: Crossfield, Samantha S R, et al.
Publicado: (2021)

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis
por: Mortimer, Isabel, et al.
Publicado: (2019)

Abatacept in the treatment of rheumatoid arthritis
por: Vital, Edward M, et al.
Publicado: (2006)

Baricitinib in the treatment of rheumatoid arthritis: clinical and ultrasound evaluation of a real-life single-centre experience
por: Tesei, Giulia, et al.
Publicado: (2021)

Rituximab experience from a single centre for patients with rheumatoid arthritis-related interstitial lung disease
por: Sahin Eroglu, Didem, et al.
Publicado: (2022)

Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis
por: Combe, Bernard, et al.
Publicado: (2022)

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2011)

The subgingival microbiomes in periodontitis and health of individuals with rheumatoid arthritis and at risk of developing rheumatoid arthritis
por: Cheng, Z., et al.
Publicado: (2017)

TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes()
por: Savic, Sinisa, et al.
Publicado: (2014)

Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial
por: Emery, Paul, et al.
Publicado: (2020)

Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?
por: Romão, Vasco C., et al.
Publicado: (2017)

Abnormal left ventricular geometry is prevalent in asymptomatic patients with established rheumatoid arthritis compared with those with early disease and healthy controls
por: Erhayiem, Bara, et al.
Publicado: (2015)

Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis.
por: Kim, Ki Chan, et al.
Publicado: (2002)

Changes in bone density and bone turnover in patients with rheumatoid arthritis treated with rituximab, results from an exploratory, prospective study
por: Wheater, Gillian, et al.
Publicado: (2018)

Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab
por: Hassan, Sabih Ul, et al.
Publicado: (2020)

COVID-19 vaccination experience in patients with rheumatoid arthritis treated at a single VA medical center
por: Abi Doumeth, Sarah, et al.
Publicado: (2023)

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
por: Gaujoux-Viala, Cécile, et al.
Publicado: (2014)

Autoantibodies to Posttranslational Modifications in Rheumatoid Arthritis
por: Burska, Agata N., et al.
Publicado: (2014)

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
por: Dougados, Maxime, et al.
Publicado: (2014)

Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia
por: Ponchel, Frederique, et al.
Publicado: (2005)

Rheumatoid Arthritis: Refractory to Infliximab, a Tumor Necrosis Factor Inhibitor
por: Solehan, Hana Maizuliana bt, et al.
Publicado: (2011)

Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Lundquist, Lisa M, et al.
Publicado: (2012)

Recurrent and refractory corneal perforation secondary to rheumatoid arthritis treated with infliximab
por: Al Saleh, Ahmed, et al.
Publicado: (2021)

Household catastrophic health expenditures for rheumatoid arthritis: a single centre study from South India
por: Bagepally, Bhavani Shankara, et al.
Publicado: (2023)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4j0ggs70d7fi3onad6riin0qq9